Medicines & Healthcare products Regulatory Agency

MHRA Freedom of Information Act (FOIA) request Disclosure Log index

This document contains reference details for all FOIA requests which have been answered in full or in part, or for which the agency held no information.

It is a fully searchable PDF which will produce a list of all requests containing the chosen search term.

If you wish to see the original request and subsequent agency reply, please send an email headed “Disclosure Log request” to:

FOI_policy@mhra.gsi.gov.uk

As long as it is headed correctly it will not be treated as a new FOIA request. The identity of the original requester will be redacted.

Updated: 1 March 2017

FOI no	*Subject*	*Date reply sent*	*Result of request*
16/569	ADRs Fluenz Tetra nasal spray suspension	21/11/2016	Disclosed in full
16/570	ADRs HPV vaccination	29/11/2016	Disclosed in full
16/571	ADRs renal dosing errors	28/11/2016	Disclosed in full
16/573	Inspection Dossier template	08/11/2016	Disclosed in full
16/574	Info on Mifegyne illicit pills being smuggled into the UK	28/11/2016	Disclosed in full
16/575	Midalozam questions	24/11/2016	Disclosed in full
16/577	Brexit implications	01/12/2016	Disclosed in part
16/579	ADRs vaccines, prescription and OTC medicines under 16s	02/12/2016	Disclosed in part
16/580	UKPAR for PL 16363/0419 Betahistine 24mg tablets	23/11/2016	Disclosed in part
16/582	Excipients in Temazepam Eliixir PL3433/0054	28/11/2016	Disclosed in part
16/583	Inspection reports with critical or major findings	05/12/2016	Disclosed in part
16/586	Cannabidiol (CBD)	06/12/2016	Disclosed in full
16/587	Intuniv® Data Exclusivity rights	09/11/2016	Disclosed in full
16/588	ADRs vaccines	07/12/2016	Disclosed in full
16/589	RMP of Methylphenidate hydrochloride	01/12/2016	Disclosed in part
16/590	Info re the risk of oral anticoagulation(Warfarin) in Children and young people, with congenital heart disease	02/12/2016	Disclosed in full
16/591	Request- Risk Management Plan for Amorolfine	21/11/2016	Disclosed in part
16/594	ADRs omeprazole, esomeprazole & lansoprazole kidney disease	02/12/2016	Disclosed in full
16/599	Request for Devices EAG Details	13/12/2016	Disclosed in full
16/600	PARS for two ibuprofen products	16/11/2016	Disclosed in full
16/601	Acyclovir as active substance	08/12/2016	Disclosed in full
16/603	Pfizer inspection reports - PV	13/12/2016	Disclosed in part
16/604	GMP Inspection report - Cobra Biologics	30/11/2016	Disclosed in part
16/605	PARs Acidex Liquid -peppermint flavour PL 04917/0027/PL 04917/0021	08/12/2016	Disclosed in full
16/606	Inspection report, Covance Harrogate	16/12/2016	Disclosed in part
16/607	Clinical Trials - Lariam/Mefloquine	19/12/2016	Disclosed in part
16/609	ADRs Hoists	28/11/2016	Disclosed in part
16/613	Info on Acidex Liquid -peppermint flavour PL 04917/0027/PL 04917/0021	16/12/2016	Disclosed in full
16/615	PAR Arcoxia (etoricoxib)	21/12/2016	Disclosed in part
16/617	List of sites inspected by MHRA in India	13/12/2016	Disclosed in full
16/618	How many MAAs MHRA received as DCPs	09/12/2016	Disclosed in full
16/620	List of GCP QA inspectors	16/12/2016	Disclosed in full

FOI no	*Subject*	*Date reply sent*	*Result of request*
16/621	Inspection report, Manx Pharma, Warwick	13/12/2016	Disclosed in part
16/622	Inspection report, Covance Harrogate	30/12/2016	Disclosed in part
16/623	Correspondence concerning CBD decision	30/12/2016	Disclosed in full
16/624	Inspection report, Bristol Myers Squibb	30/12/2016	Disclosed in full
16/626	Details concerning the formerly approved medicinal product Aramine 10 mg/mL solution for injection (PL 00025/5020R).	21/12/2016	Disclosed in part
16/630	Questions on Prozac	05/01/2017	Disclosed in full
16/632	Drug approval for Imatinib Mesylate	03/01/2017	Disclosed in full
16/633	Assessment report for Pravagettes	30/12/2016	Disclosed in part
16/634	A list of all medicines for which marketing authorisation has been applied for (successfully and unsuccessfully)	06/01/2017	Disclosed in part
16/637	Summary of Product Characteristics (SmPC) and patient information leaflet for the medicine Retinova	08/12/2016	Disclosed in part
16/639	Information concerning side effects of Kenalog injections and vitamin D3 injections	06/01/2017	Disclosed in full
16/642	Serious Adverse Events (SAEs) arising from Phase I and Phase II trials	09/01/2017	Disclosed in part
16/643	Maverick spending amounts, and procurement team information	22/12/2016	Disclosed in full
16/645	Marketing authorisation and patient information for Emeside Capsules Summary of product characteristics for the product	14/12/2016	Disclosed in full
16/646	Copies of all GMP post inspection letters from 2015 and 2016. To include all letters irrespective of whether the case folder is closed or whether there are critical deficiencies.	12/01/2017	Disclosed in part
16/648	Tibolone (Livial): benefit-risk evaluation 2007 London: MHRA UK public assessment	14/12/2016	Disclosed in full
16/649	Breakdown of spontaneous ADR reports involving off-label drug use	15/01/2016	Disclosed in full
16/650	Inspection of Kopran Ltd	16/01/2017	Disclosed in part
16/651	Correspondence between MHRA and media organisations in relation to HPV vaccines	18/01/2017	Disclosed in part
16/652	Adverse incidents involving Essure	13/01/2017	Disclosed in part
16/653	Yellow Card reports on Schedule 20, Part 2 of the Human Medocomes Regulation	16/01/2017	Disclosed in full
16/655	Marketing authorisation, Imatinib Teva	30/12/2016	Disclosed in part
16/656	Risk Management Plan for Sayanaject 104 mg	16/01/2017	Disclosed in part
16/657	Questions about BIA-ALCL in women with breast implants	23/01/2017	Disclosed in full
16/658	Information for 2016 on adverse event and product recalls relating to implantable medical devices	17/01/2017	Disclosed in part
16/659	Inspection report, Selcia Limited	20/01/2017	Disclosed in part
16/660	Questions about Azzalure	17/01/2017	Disclosed in full
16/661	Questions in relation to transvaginal mesh implants	26/01/2017	Disclosed in part
16/663	Environmental risk assessment for Elvanse Capsules (lisdexamfetamine dimesylate)	16/01/2017	Disclosed in part
16/664	Information on RobiCold	09/02/2017	Disclosed in part
17/001	Clinical Trials for Licence to Prescribe Synthetic Insulin	24/01/2017	Disclosed in part
17/002	ADRs for Fluoxetine	24/01/2017	Disclosed in full

FOI no	*Subject*	*Date reply sent*	*Result of request*
17/003	PAR Nurofen Cold & Flu / Nurofen Sinus HCl tablets	21/02/2017	Disclosed in part
17/004	CBD oil - names of companies written to	31/01/2017	Disclosed in part
17/007	Inspection reports for BioReliance - Glasgow	26/01/2017	Disclosed in part
17/009	Minutes of board meetings	03/02/2017	Disclosed in part
17/012	CPRD data requests, releases and knowledge	12/01/2017	Disclosed in part
17/013	Sodium Valproate Warnings timescale	06/02/2017	Disclosed in full
17/015	ADRs to new teratogenic drugs 1970's	06/02/2017	Disclosed in full
17/016	Inspection reports - 10 different companies	07/02/2017	Disclosed in part
17/017	ADRs cardiac arrest	06/02/2017	Disclosed in part
17/019	SPC's, PARs, RMPs for Cannabidiol	08/02/2017	Disclosed in part
17/020	ADR's from Scotland for HPV Vaccine since 2008	06/02/2017	Disclosed in full
17/021	Information on notified imports - Indigo Carmine	25/01/2017	Disclosed in full
17/023	Co-Cyprindiol ADR reports	08/02/2017	Disclosed in full
17/024	Numbers of Grade 7 and above staff	10/02/2017	Disclosed in part
17/026	Request for approval documents - Larium	10/02/2017	Disclosed in part
17/027	HPV vaccine and girls losing hair following vaccination	08/02/2017	Disclosed in part
17/029	CBD - questions on evidence and companies	18/01/2017	Disclosed in full
17/030	Data request Product Azzalure and Dysport	14/02/2017	Disclosed in part
17/031	Report on the safety of mumps vaccines	09/02/2017	Disclosed in part
17/033	Adverse reactions for various herbal medicines	13/02/2017	Disclosed in full
17/034	Correspondence took place with media organisations in November and up to 15th December 2016	26/01/2017	Disclosed in full
17/035	Licence holders for Nitisinone	25/01/2017	Disclosed in full
17/036	Organisational chart showing each post by title	16/02/2017	Disclosed in part
17/037	ADRs for various products	20/02/2017	Disclosed in full
17/038	SUSAR related deaths that occurred each year from and including 2010 to 2016	06/02/2017	Disclosed in full
17/043	List of CBD manufacturers the Agency has written to	31/01/2017	Disclosed in part
17/045	PAR for Gabapentin 50mg/ml oral solution - PL 41344/0028 & PL 004427/0155 and Regaine for Men Extra Strength - 5% cutaneous solution - PL 15513/0365 & PL 10263/0038.	31/01/2017	Disclosed in part
17/046	The first 60 MAs for Oxycodone since 2005	08/01/2017	Disclosed in full
17/047	Hoffman La Roche's 1989 Application for Marketing Authority for Lariam (Mefloquine) and Hoffman La Roche's Periodic Safety Update reports for Lariam from 1990 to date.	24/02/2017	Disclosed in part
17/048	EPAR for product Gelofusine Ecobag (PL 03551/0047)	22/02/2017	Disclosed in part
17/049	ADR for the drug Fluoxetine reported since 2012 to date	23/02/2017	Disclosed in full
17/050	Staff on organisation payroll in 2013/2014, 2014/2015, 2015/2016 & total number of staff earning more than £100,000 2013/14, 2014/15 and 2015/2016	28/02/2017	Disclosed in part

FOI no	*Subject*	*Date reply sent*	*Result of request*
17/051	A breakdown of all alleged side effects associated with Ropinirole	28/02/2017	Disclosed in full
17/052	Adverse sexual affects caused by SSRIs	27/02/2017	Disclosed in full
17/055	Enquiring in to Subutex RMP	27/02/2017	Disclosed in full
17/061	MHRA has been informed of any such mechanical failure of peripheral arterial catheters?	13/02/2017	Disclosed in full
17/062	Total amount spent on Managed Services 2014, 2015 & 2016 and cloud services 2014, 2015, 2016	28/02/2017	Disclosed in full